arrow
M

Martin Højgaard

department of oncology
H指数:9
被引数:548

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive reanalysis of 2,040 undiagnosed clinical whole-genome sequencing cases improves diagnostic yield

对2,040例未诊断临床全基因组测序病例的全面再分析提高了诊断率

2026-08-110
OA
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids

组织学保真度和转移性患者来源类器官的微环境激酶组特征

2026-04-030
OAAI
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform

精准癌症医学平台中患者匹配类器官药物反应的免疫细胞调节

Cells
IF5.2
2026-01-300
OAAI
Copenhagen Prospective Personalized Oncology (CoPPO)—impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting

哥本哈根前瞻性个性化肿瘤学(CoPPO)——在I期研究中对超过2000例患者进行综合基因组分析的影响

2025-04-150
PRE
Individualised schedule optimisation improves rates and severity of anaemia in patients ( pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
2024-10-010
PRE
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
2024-05-062
OAAI
Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
2023-12-010
PRE
MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
2023-12-015
PRE
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
2023-06-0530
OAAI
Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
2023-04-140
PRE
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
2023-02-2216
OAAI
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

larotrectinib在TRK融合阳性原发性中枢神经系统肿瘤中的疗效和安全性

2021-11-2794
OAAI
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor
2021-11-1713
OA